Katie Ching, PhDResearch Investigator at Ligand Pharmaceuticals, Inc.
Dr. Ching is a Research Investigator at Ligand Pharmaceuticals in Emeryville, CA. She received her Ph.D in Biochemistry and Molecular Biology from Georgetown University, followed by post-doctoral studies at the National Institutes of Health in Bethesda, Maryland. At Ligand, she has been responsible for the evaluation and characterization of transgenic chickens used for the discovery of human antibodies. The original transgenic platform, OmniChickenTM, has been used for antibody discovery programs by pharmaceutical industry partners since 2016.